Galapagos increases share capital through warrant exercise by Gilead
November 06 2019 - 4:01PM
Mechelen, Belgium; 6 November 2019,
22.01 CET; regulated information – Galapagos NV (Euronext &
NASDAQ: GLPG) announces a share capital increase arising from a
warrant exercise by Gilead.
On 1 November 2019, Galapagos NV (the
"Company" or "Galapagos")
announced that Gilead Therapeutics A1 Unlimited Company, an
affiliate of Gilead Sciences, Inc. (NASDAQ: GILD)
("Gilead"), delivered an exercise notice to
Galapagos in order to exercise the Initial Warrant A.
Initial Warrant A, approved by Galapagos'
shareholders on 22 October 2019, entitles the holder thereof to
subscribe for a maximum number of shares that is sufficient to
bring the number of shares owned by Gilead and any of its
affiliates to 25.1% of the actually issued and outstanding shares
immediately after the issue of the shares that are to be issued
upon the relevant exercise of Initial Warrant A. Initial Warrant A
has a term of one year starting as of 22 October 2019.
As a result of the exercise of the Initial
Warrant A, Gilead subscribed for 2,617,791 shares at €140.59 per
share for a total of €368,035,236.69. The new shares were issued on
6 November 2019.
In accordance with Belgian transparency
legislation1, Galapagos notes that its total share capital
currently amounts to €349,274,259.52, the total number of
securities conferring voting rights is 64,571,622, which is also
the total number of voting rights (the "denominator"), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (warrants) to
subscribe for not yet issued securities conferring voting rights
consists of (i) 5,636,297 warrants under several outstanding
employee warrant plans, which equals 5,636,297 voting rights that
may result from the exercise of those warrants, and (ii) two
warrants issued to Gilead Therapeutics to subscribe for a maximum
number of shares that is sufficient to bring the shareholding of
Gilead and its affiliates to 25.1% and 29.9%, respectively, of the
actually issued and outstanding shares after the exercise of the
relevant warrant. Galapagos does not have any convertible bonds or
shares without voting rights outstanding.
About GalapagosGalapagos
(Euronext & NASDAQ: GLPG) discovers and develops small molecule
medicines with novel modes of action, three of which show promising
patient results and are currently in late-stage development in
multiple diseases. Our pipeline comprises Phase 3 through to
discovery programs in inflammation, fibrosis, osteoarthritis and
other indications. Our ambition is to become a leading global
biopharmaceutical company focused on the discovery, development and
commercialization of innovative medicines. More information at
www.glpg.com.
Contacts
Investors:Elizabeth GoodwinVP
Investor Relations +1 781 460 1784
Sofie Van GijselDirector Investor Relations+32
485 19 14 15ir@glpg.com
Media:Carmen VroonenSenior
Director Communications & Public Affairs+32 473 824 874
Evelyn FoxDirector Communications+31 6 53 591
999communications@glpg.com
Forward-looking statementsThis
release may contain forward-looking statements. Such
forward-looking statements are not guarantees of future results.
Theseforward-looking statements speak only as of the date of
publication of this document. Galapagos expressly disclaims any
obligation to update any forward-looking statements in this
document, unless specifically required by law or regulation.
1 Belgian Act of 2 May 2007 on the disclosure of major
shareholdings in issuers whose shares are admitted to trading on a
regulated market and containing various provisions.
Galapagos (EU:GLPG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Oct 2023 to Oct 2024